1. Pink Sheet
  2. >>Market Access

FDA, Medicare And The Future Of Coverage With Evidence Development For Accelerated Approvals

 
• By Cathy Kelly

Health policy experts discuss ways Medicare coverage policy may evolve in the coming years and how efforts to smooth the transition between accelerated drug approvals and Medicare reimbursement decisions could play out.

Will Reimbursement Continue To Be Bumpy After Accelerated Approval? • Source: Shutterstock

The Centers for Medicare and Medicaid Services should take a page from the US Food and Drug Administration's playbook when it comes to the way it educates stakeholders about its coverage with Medicare evidence development policy for accelerated approvals, suggested former CMS chief medical officer Sean Tunis, now a principal with Rubix Health.

Key Takeaways

  • CMS should release more detailed guidance on CED and Congress may need to pass legislation clarifying and codifying the policy.

Specifically, CMS should develop detailed guidance on when it will use Medicare coverage with evidence development, what that evidence development...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 
• By Sarah Karlin-Smith

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.

First Among Equals: US FDA CBER Director Prasad Gains Agency-Wide Authority

 
• By Bridget Silverman

As Chief Medical and Scientific Officer, Vinay Prasad will advise the FDA Commissioner on cross-cutting issues, provide strategic leadership and be a public face of the agency.

Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla

 
• By Neena Brizmohun

Eisai and Lilly explain why they disagree with today’s conclusion by the health technology assessment institute, NICE, that the benefits of their respective drugs for Alzheimer’s disease are too small to justify the additional cost to the National Health Service.